Global Endoscopes Market – Analysis By Product Type, Application End User, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 – Yahoo Finance

Read Time:9 Minute, 0 Second

Executive Summary The Global Endoscopes or endoscopy devices market is projected to display a significant growth represented by a CAGR of 6. 50% during 2021 – 2026. The global Endoscopes market was valued at USD 10.
New York, Nov. 09, 2021 (GLOBE NEWSWIRE) — announces the release of the report "Global Endoscopes Market – Analysis By Product Type, Application End User, By Region, By Country: Market Insights and Forecast with Impact of COVID-19" –
97 billion in the year 2020 with North America region leading the regional market share. Increasing preference for minimally invasive surgeries, rising prevalence of chronic diseases (cancer, heart diseases, gastrointestinal diseases ), aging population, increasing healthcare expenditure and introduction of new endoscopic products are the major factors that are expected to boost the demand of endoscopes in the region. Meanwhile, the demand in developed economies is already really high and the future growth is going to remain quite significant.

However, the Asia Pacific region is expected to witness lucrative growth over the forecast period owing to high demand for endoscopic procedures along with improving healthcare infrastructure that will drive the market for Endoscopes in the forthcoming years. Intense competition among endoscopes makers exists due to the increasing demand for endoscopes for various diagnostic and therapeutic procedures, coupled with technological advances. Increasing market demand is likely to encourage entry of new companies in the future, driven by the increasing awareness and acceptance of endoscopes and related technologies.

The COVID-19 is an incomparable global public health emergency that has affected almost every industry, including the endoscopes, non-urgent surgical care and other healthcare industries in multiple ways. The COVID-19 episode has disrupted the market of Endoscopes in different nations because of lockdowns, travel boycotts, and implementation of stay-at-home orders. The highly infectious nature, hospitalization and mortality rates associated with COVID-19 has impacted clinical care for many life-threatening conditions and has quite naturally postponed many non-urgent surgical or endoscopic procedures in order to minimize the risk of infection and to compliance with various governmental orders. As, the healthcare resources, including the surgical and endoscopy centers were deviated towards Covid care.

Rising prevalence of chronic diseases, increasing adoption of endoscopes for treatment and diagnosis, and technological advancements leading to enhanced applications of endoscopes. Furthermore, the growing preference for minimally-invasive surgeries over traditional/open surgeries are driving the utilization of various endoscopic procedures for diagnosis, such as gastrointestinal endoscopy, laparoscopy, arthroscopy, cystoscopy etc. These factors, in turn, are projected to fuel the demand for Endoscopes over the coming years.

One of the global leaders in medical devices industry, Olympus Corporation has focused on endoscopes innovation and some strategic M&A activity. For instance, in 2020, the company announced their U.S. FDA approved new and most advanced endoscopy system EVIS X1, it will improve outcomes from disorders of the stomach, colon, and oesophagus, as well as from bronchial diseases, by providing every endoscopists with innovative and proven tools worldwide. Alongside, in 2021, the company acquired Quest Photonic Devices B.V. (Netherlands) to strengthen its surgical endoscope business and add abdominal surgical instruments to its portfolio.

Scope of the Report
• The report presents the analysis of Endoscopes Market for the historical period of 2016-2020 and the forecast period of 2021-2026.

• The report analyses the Endoscopes Market by value (USD Millions).

• The report analyses the Endoscopes Market by Product Type (Flexible Endoscopes, Rigid Endoscopes, Others).

• The report analyses the Endoscopes Market by Application (GI endoscopy, Laparoscopy, Arthroscopy, Others)

• The report analyses the Endoscopes Market by End User (Hospitals, Ambulatory Surgical Centers, Others)

• The Global Endoscopes Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA).

• The Global Endoscopes Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, Australia).

• The key insights of the report have been presented through the frameworks of SWOT Analysis and Porter Five Force Analysis. Also, the attractiveness of the market has been presented by region, by Product Type, by Application and by End User.

• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product developments. The companies analysed in the report include Olympus, Johnson & Johnson, Boston Scientific, Stryker Corporation, ConMed Corporation, Hoya Corporation, Medtronic, Steris Corporation, Fujifilm, Karl Storz SE.

Key Target Audience

• Endoscopes products or Endoscopy devices Manufacturers

• Pharmaceutical Industry

• Biotechnology Companies

• Government and Research Organisations

• Consulting and Advisory Firms

• Investment Banks and Equity Firms
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


The Mad Money host says the virtual world will transform many industries.
Dow Jones futures turned lower Wednesday morning. Tesla stock jumped 4% after Chief Executive Elon Musk said he had sold "enough stock."
When stocks fall in price, it’s frequently a signal for renewed investor interest. After all, low share prices offer a chance to live up to the old market advice, ‘buy low and sell high.’ What investors need is some way to tell the underlying reasons for a drop in share price, whether it bodes well or ill for the stock. One of the best stock signals comes from corporate insiders, the company officers who hold positions of high responsibility – to their Boards, and to their peers, and to their sh
In 2021, BlackBerry Limited (NYSE: BB)reached a valuation not seen in many years. Unfortunately, those were not sustainable moves as short-squeezes are like a tide – they eventually have to withdraw. Yet, the company cannot rely on retail trends to prop the valuation up; at this stage, the priority should be revenue growth.
Viatris' (NASDAQ: VTRS) valuation is so low that I had to double-check the numbers. If Viatris chose to use its profits on stock buybacks, it could scoop up every outstanding share by mid-2025. Viatris' main priorities for using its capital are to pay down debt and to fund its dividend program.
Not every stock with big potential has shot through the roof this year.
Some retirement advisors are cautioning that the famous 4% Rule no longer works. But the inventor of the 4% Rule says you can actually withdraw 4.7%.
With less than two weeks remaining in 2021, the major Wall Street firms and analysts have pulled out their crystal balls to peer through the curtains at what awaits for 2022. It’s an annual habit, and one that investors pay close attention to; while the forecasts are not always perfect, they do give a fair perspective of marketing terrain. According to investment banking firm Raymond James, there are going to be plenty of opportunities in the year ahead. The firm's stock analysts have been busy
(Bloomberg) — Chinese technology shares listed in Hong Kong trimmed an earlier advance after local media reported that cooperation had been suspended between an Alibaba Group Holding Ltd. unit and a government agency.Most Read from BloombergOmicron at Least Doubles Risk of Getting Infected on a PlaneFDA Expected to Authorize Pfizer and Merck Covid Pills This WeekIsrael to Offer Fourth Shots; N.Y. Cancels Exams: Virus UpdateExtreme Bidding Wars Are Raging in One of World’s Riskiest Housing Marke
Jose Castillo pulled his $60,000 worth of GameStop Corp shares from his brokerage last summer, even though he had no intention of selling them. The 26-year-old information technology worker, who lives in the greater Minneapolis area, is among a growing number of investors in "meme" stocks — shares such as GameStop popular with day traders — who are withdrawing them from brokerages out of concern the shares will be lent to hedge funds engaging in short-selling. Castillo pulled the shares out of Fidelity Investments and transferred them to his name using Computershare Ltd, an Australian stock transfer company.
Tesla CEO Elon Musk said he had sold "enough stock" to reach his plan to sell 10% of his shares in the world's most valuable car company, according to an interview released on Tuesday. The billionaire, who moved the company's headquarters from California to Texas this month after his personal move last year, also slammed California for "overtaxation." Tesla shares, which had hovered near record-highs, lost about a quarter of their value after Musk said on Nov. 6 he would sell 10% of his stake if Twitter users agreed.
Intel announced in October 2020 that it would sell its NAND memory and storage business to focus on the more lucrative Optane memory business.
With all the focus on omicron and a big marketwide rebound, Microsoft had two significant announcements you may have missed.
Shares of Rivian Automotive (NASDAQ: RIVN) jumped 7.6% on Tuesday, halting the recent plunge in its stock price. Rivian's shares, like that of many premium-priced growth stocks, had been hit hard in recent weeks as investors responded to the prospect of higher inflation and corresponding rate hikes by the Federal Reserve. Investors tend to value future earnings less when interest rates rise.
The latest omicron news, plus a formal complaint from a top global charity, made some investors head for the exit.
Stock futures pointed to a lower open to give back some gains from Tuesday's session, when the major equity indexes recouped some losses after three consecutive sessions of declines.
Electric vehicle stock Nio (NYSE: NIO) rebounded sharply on Tuesday, surging 6.3% as of 12:15 p.m. ET. The broader market rebound, ever-rising demand for new energy vehicle (NEV) sales in China, the U.S. Environmental Protection Agency's (EPA) latest greenhouse gas emission standards that hugely favor EVs, and Nio's own growth plans are just some of the factors that sent the EV stock flying. Investors wanting to cash in on the EV boom seemed to have found multiple reasons to buy Nio shares today.
The company reported better-than-expected revenues as customers moved in greater number to cloud-based software.
In this article, we’ll discuss Jim Cramer’s most favorite tech stocks to buy now. You can skip our detailed analysis of Cramer’s background and tech stocks, and go directly to read Jim Cramer’s 5 Most Favorite Tech Stocks to Buy Now. Jim Cramer is one of the most prominent names in the investment world. His […]
The administration has been calling for more output to rein in gasoline prices, but producers say its climate-change focus is a brake on more drilling.


0 %
0 %
0 %
0 %
0 %
0 %

Average Rating

5 Star
4 Star
3 Star
2 Star
1 Star

4,721 thoughts on “Global Endoscopes Market – Analysis By Product Type, Application End User, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 – Yahoo Finance